v116517
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2011 (NCT02695745)
Timeline
Indications
Mechanism of action
- Vanilloid receptorANTAGONIST
TRPV1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-(3-chloro-5-(1,2-dihydroxyethyl)-2-pyridyl)-n-(5-(trifluoromethyl)-2-pyridyl)-3,6-dihydro-2h-pyridine-1-carboxamide
- v116517
- v116517
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01688934 | Phase 2 | Sep 1, 2012 | Purdue Pharmaceuticals |
| NCT01688947 | Phase 2 | Sep 1, 2012 | Purdue Pharmaceuticals |
| NCT02695745 | Phase 1 | Sep 1, 2011 | Purdue Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Purdue Pharmaceuticals | For profit | 3 | 3 | 2 | 2011 |
1 organizations
Page 1 / 1